Venlafaxine is an antidepressant drug that is being evaluated for the treatment of hot flashes in women who have breast cancer.
A new study in Personalized Medicine in Psychiatry explores how specific clinical and biological signals can help doctors select the most effective drug more quickly and with greater precision.
Although drug therapy is the accepted first-line treatment for panic disorders, 17% to 64% of patients do not respond adequately and continue to exhibit one of the most common symptoms of PD, the panic attack.
A new Université de Montréal study in the British Medical Journal reveals that antidepressants prescribed to pregnant women could increase the chance of having a baby with birth defects.
Seafood is the main component of European Christmas menus. But with rising concern about chemical pollution in the marine environment, is seafood safe to eat?
The majority of antidepressants prescribed to treat children and teenagers with major depression are ineffective and may even be unsafe, warn researchers.
An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.
Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.
More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.
Some three-quarters of North American women have menopausal hot flashes, but many cannot use hormones for medical reasons or choose not to. Numerous products and techniques are promoted for hot flashes, but do they work, and are they safe? To answer these questions, a North American Menopause Society panel of experts weighed the evidence and made recommendations in a position statement, "Nonhormonal management of menopause-associated vasomotor symptoms," published online today in the Society's journal, Menopause.
A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.
A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.
A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.
The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results.
Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.
Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.
Patients with major depression who fail to see improvement after taking an antidepressant often have their initial medication switched or combined with a second drug. Many clinicians weigh the possibility of adverse side effects when deciding between strategies. New research in the latest issue of General Hospital Psychiatry now suggests one strategy may not be any more likely to be harmful than the other.
Older people taking new generation antidepressants are at more risk of dying or suffering from a range of serious health conditions including stroke, falls, fractures and epilepsy, a study involving researchers at The University of Nottingham has found.
Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School.
Dr. Reddy's Laboratories today announced that it has launched three products in the US market.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Venlafaxine Hydrochloride Extended-release Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR Capsules, which are used in the treatment of major depressive disorder and social anxiety disorder.